SCHEMBL2534178

SCHEMBL2534178

CC(C)(C)Oc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 18/20 0.63
ROCK2 O75116 17/20 0.63
PRKACA P17612 17/20 0.63
CDK2 P24941 17/20 0.63
HIPK2 Q9H2X6 17/20 0.63
PIM1 P11309 16/20 0.63
GSK3B P49841 16/20 0.63
CLK4 Q9HAZ1 12/20 0.63
MAP4K4 O95819 12/20 0.63
CDK7 P50613 9/20 0.63
CDK9 P50750 9/20 0.63
DYRK1A Q13627 8/20 0.63
MELK Q14680 8/20 0.63
STK17A Q9UEE5 8/20 0.63
DAPK3 O43293 7/20 0.63
CLK2 P49760 7/20 0.63
PRKX P51817 7/20 0.63
CDK5 Q00535 7/20 0.63
PKN2 Q16513 7/20 0.63
PRKD3 O94806 6/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2534550 0.84 BRD4 (0.50) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1043490 0.84 CDC7 (0.82) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL20765255 0.82 BRD4 (0.51) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL30380153 0.82 BRD4 (0.51) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL28805250 0.82 DYRK1A (0.49) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL2528281 0.82 DYRK1A (0.46) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL2534175 0.81 DYRK1A (0.51) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL2525011 0.81 BRD4 (0.47) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL2528668 0.80 DYRK1A (0.49) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL2529657 0.80 BRD4 (0.48) CDC7ROCK2PRKACACDK2HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181246-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2015-11-10 US disclosed
US-20140357616-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2014-12-04 US disclosed
US-8822446-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2014-09-02 US disclosed
CN-103003274-A Pyrrolopyridine inhibitors of kinases ABBVIE INC 2013-03-27 CN disclosed
US-20110257152-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357616-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885ROCK2 373/4885PRKACA 78/4885
US-20110257152-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885ROCK2 373/4885PRKACA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.